MapLight Therapeutics, Inc. MPLT R2KPHARMA
Company Overview
MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders. The company's products include ML-007C-MA, a fixed-dose combination of an M 1 /M 4 muscarinic agonist for the treatment of schizophrenia and Alzheimer's disease psychosis; ML-004 for the treatment of social communication deficit and/or irritability in autism spectrum disorder; ML-021 for the treatment of motor deficits in Parkinson's disease; ML-055 for the treatment of neuropsychiatric conditions; and ML-009, a G-protein-coupled receptor 52 positive allosteric modulator for the treatment of hyperactivity, impulsivity and agitation-related disorders. The company also develops platform identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation. The company was formerly known as Alvarado Therapeutics, Inc. and changed its name to MapLight Therapeutics, Inc. in August 2019. MapLight Therapeutics, Inc. was incorporated in 2018 and is based in Redwood City, California.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -24.92% |
| 6 Months: | -25.61% |
| 3 Months: | -50.84% |
| 1 Month: | +3.69% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)43.71 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 65.4% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | MPLT MapLight Therapeutics, Inc. R2KPHARMA | 13.77 | -3.12 | $586.85M | 0.00% | -36.50% | -80.95% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Operating Income | - | - | -20.89M | -23.54M | - | -31.50M | -64.50M |
| Net Income | -18.93M | -18.40M | -19.02M | -22.34M | -29.85M | -29.42M | -60.67M |
| Diluted EPS | - | - | -25.08 | -29.33 | - | -37.18 | -1.34 |
| R&D Expense | - | - | 16.81M | 19.79M | - | 27.09M | 53.68M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Operating Income | -82.95M | -169.08M |
| Net Income | -77.58M | -161.15M |
| Diluted EPS | -105.38 | -18.56 |
| R&D Expense | 68.52M | 138.35M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Total Assets | - | 136.92M | 479.51M |
| Total Equity | -117.58M | -193.63M | 458.37M |
| Cash & Equivalents | - | 38.25M | 46.73M |
| Total Liabilities | - | 21.72M | 21.14M |
| Current Liabilities | - | 15.92M | 16.23M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Operating Cash Flow | -78.81M | -138.14M |
| Investing Cash Flow | -80.79M | -323.21M |
| Financing Cash Flow | 118.06M | 469.82M |
| Capital Expenditure | -770.00K | -473.00K |
| Free Cash Flow | -79.58M | -138.61M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Gross Margin % | - | - |
| Operating Margin % | - | - |
| Net Margin % | - | - |
| ROE % | 40.1% | -35.2% |
| ROCE % | -68.6% | -36.5% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Novo Holdings A/S | 7.95% | 3.69M | $46.45M |
| 2 | FCPM III Services B.V. | 6.96% | 3.23M | $40.65M |
| 3 | T. Rowe Price Investment Management, Inc. | 6.00% | 2.78M | $35.05M |
| 4 | Goldman Sachs Group Inc | 4.20% | 1.95M | $24.55M |
| 5 | Price (T.Rowe) Associates Inc | 3.07% | 1.42M | $17.93M |
| 6 | Blackrock Inc. | 2.21% | 1.03M | $12.92M |
| 7 | Nan Fung Group Holdings Limited | 2.09% | 971.25K | $12.24M |
| 8 | 5AM Venture Management, LLC | 2.05% | 950.01K | $11.97M |
| 9 | Sanofi | 1.97% | 912.04K | $11.49M |
| 10 | State Street Corporation | 1.84% | 852.15K | $10.74M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for MPLT
Is MapLight Therapeutics (MPLT) Fully Valued As Its Shares Hold Near $36.56? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxNTFpmczdJWmt2OHdZYmd4STdZd1pCbHBnbXVBSFA3OV82ZkpKZVItOE5OYjNWQWlmZGRVUTl3aHA2SzV5bDk5bU9YbG5Ed25rRzJyM2JjSGEzOUZsZ0lIS3ZMN1RiNUxvWi0tR1Zha0hzV19zN1l3dDIwZlJ4amJjRy1UTEtLbG9JSnJxMn…
MapLight (NASDAQ: MPLT) grants CEO 93,955 options and 23,145 RSUs - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxQb25wcHBmV2ZubTNUeUg0X3BWQ18zT2p6czB5YlNJd2lTU0VTRFgxUnFadWs0c3JVSWtGelNRLVlOQW5Fb2drcHN1MFo5SFZxRVdRX1EtSTRzcWQwWDdJaFNlN29PTjlUaUhuR3prN0Rqa245RFo1Qjk4ZXRJQng1X1IzZXJZMnQ1VUZfYj…
MPLT Stock Plunges 73% — Wipes Out Over $1B In Market Cap After Trial Miss On Once-Daily Dose - TradingView
<a href="https://news.google.com/rss/articles/CBMi4wFBVV95cUxPOUdJb2JxSjRHTjB2eGNoRDJmSXctemxxZ2lWRlBHWmJyeE9ZcmFrRzE3aEJvQ2N6N3pGSXpJVS1IY0hieHB0d2s3cThQcGtzZGRHRnh1bE01LUFKVjlIcHRoT25EVmJPQWZuQ01uR1FDNm1FODZHbDV1T1lHMUlaak9nWlFSczdObEI5eV…
BlackRock Inc. Takes $36.74 Million Position in Maplight Therapeutics, Inc. $MPLT - marketbeat.com
<a href="https://news.google.com/rss/articles/CBMi0gFBVV95cUxPY25yMXpxcXJMVTJvc2JkV2ZDdlUyNEVhRU9BejM3ZndsS29zd1hsMnJKQWRUY2Fzb2EyZE5vYzk1NE56SnNmSTRaWS05aEpsbjV6bGd4eUhXdVp1WlBtTTl3MVhKZ1J1SnBtd2xrSlVGN1NKckRrcnR5VUU2dDBhaGN3Z2d2OUxlRjhQT0…
MPLT Stock Plunges 73% — Wipes Out Over $1B In Market Cap After Trial Miss On Once-Daily Dose - Stocktwits
<a href="https://news.google.com/rss/articles/CBMi6gFBVV95cUxQZUtySWwwdldNTWVmZTFMUktidHgwbUY4VjZ4V2JQbWFObGVyaklpN2hOWmlqd0FrdDRwQ1Q1dzRRZHJWUmN6UVFRZXgyOHk1UENHTEpvQUw2SURsZERzZDI2YVh5Q0E1NzdtMERLLW13V01pR0R0Q05xMXduTzJlcVpqVjNIQ0M1YmoyMV…
Insider Sale: CAO and Interim CFO of $MPLT Sells 1,476 Shares | MPLT Stock News - quiverquant.com
<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxOMnM1cU9QbEQxYndvalA2MXU4QjE4anF4SEVJMEwxX0ZDU1QyczNBOUNRX2syUUJscTNQZHM1U0FUanJFZGFCeHJKTjh2Z1JHazdqdVZXbjV2R0c1RVp6Q0hGbFFPWElmcWNsUk4xM09jRi1wWWhrcXphTkZ1ZWExS0lWdFB4em1HdW5abn…
MPLT — Frequently Asked Questions
What is the current share price of MapLight Therapeutics, Inc. (MPLT)?
As of 2026-09-07 16:24 PDT, MapLight Therapeutics, Inc. (MPLT) trades at $13.77 on NasdaqGS. Its 52-week range is $9.90 to $39.80.
What is the market capitalisation of MPLT?
MapLight Therapeutics, Inc. (MPLT) has a market capitalisation of $586.85M on NasdaqGS.
What is the P/E ratio of MPLT?
MPLT trades at a trailing price-to-earnings (P/E) ratio of -3.12. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 1.38.
What is the return on equity (ROE) of MPLT?
MPLT has a return on equity (ROE) of -80.95%. Its return on capital employed (ROCE) is -36.50%.
Is MPLT a good stock to buy?
This page provides a data-driven analysis of MapLight Therapeutics, Inc. (MPLT), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.